8
Jan
2026
Following the Science to Immunology: Kate Haviland on The Long Run
Kate Haviland is today’s guest on The Long Run. Kate is the former CEO of Cambridge, Mass.-based Blueprint Medicines. Blueprint was one of the big biotech success stories of 2025. The company was acquired by Sanofi for $9.1 billion in cash at closing, and potentially $9.5 billion if certain milestones are met. The company started out with a vision for... Read More
